| Bid | 180.03 |
| Market Cap | 20.21B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -8.19 |
| PE Ratio (ttm) | -22.55 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 189.93 |
| Volume | 329,397 |
| Avg. Volume (20D) | 369,150 |
| Open | 184.00 |
| Previous Close | 183.81 |
| Day's Range | 183.91 - 187.42 |
| 52-Week Range | 126.97 - 248.16 |
| Beta | undefined |
About BGNE
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tu...
Analyst Forecast
According to 8 analyst ratings, the average rating for BGNE stock is "Strong Buy." The 12-month stock price forecast is $274, which is an increase of 48.34% from the latest price.
Next Earnings Release
Analysts project revenue of $1.04B, reflecting a 63.93% YoY growth and earnings per share of -0.8, making a -77.34% decrease YoY.
1 month ago · seekingalpha.com
BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And USBeiGene's TEVIMBRA was just approved by the European Commission. The drug is poised to enter the EU and just reached the US market in October. BeiGene's revenue per share has grown significantly, with...
2 months ago · businesswire.com
BeiGene Announces Third Quarter 2024 Financial Results and Corporate UpdatesSAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from t...
2 months ago · seekingalpha.com
BeiGene: TEVIMBRA European Push Continues With Positive CHMP OpinionBeiGene, Ltd.'s TEVIMBRA shows promise with label expansion in Europe for 1st-line gastro/gastroesophageal junction cancer and 1st-line esophageal squamous cell carcinoma. BRUKINSA, a BTK inhibitor, g...
2 months ago · businesswire.com
BeiGene to Present at the Jefferies London Healthcare ConferenceSAN MATEO, Calif. and BASEL, Switzerland--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in ...
3 months ago · businesswire.com
BeiGene Highlights Waldenström's Macroglobulinemia Innovation at IWWM 2024SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research from studies evaluating...
